Images are for illustrative purposes only.
Livagen
Livagen is the tetrapeptide Lys-Glu-Asp-Ala (KEDA), molecular weight approximately 461 Da, originally derived from research on bovine liver tissue extracts. It is described as a dual-action hepatic and immune bioregulator, with proposed activity in both liver parenchyma and lymphocyte populations.
Unlike the majority of named bioregulators in this class, which share the Ala-Glu-Asp N-terminal tripeptide, Livagen begins with the basic residue lysine, giving it a distinct electrostatic and structural profile. That places it in the KED group with Vesugen and Testagen (KED), Pancreagen (KEDW), and Prostamax (KEDP) rather than the AED group. Against Ovagen, the other liver-oriented peptide, Livagen is the longer molecule and the one carrying the immune component. Its most frequently cited research concerns chromatin decondensation and the resulting influence on gene accessibility, studied alongside hepatocyte function and lymphocyte activation.
Supplied as a lyophilized 10-vial 20mg kit for in vitro research use only.